Bristol-Myers Squibb (NYSE:BMY) was upgraded by research analysts at Jefferson Research from a “sell” rating to a “hold” rating in a report released on Tuesday, AnalystRatings.NET reports.
A number of other firms have also recently commented on BMY. Analysts at Credit Suisse reiterated a “focus list” rating on shares of Bristol-Myers Squibb in a research note to investors on Monday. They now have a $55.00 price target on the stock. Separately, analysts at Morgan Stanley upgraded shares of Bristol-Myers Squibb from an “equal weight” rating to an “overweight” rating in a research note to investors on Monday. They now have a $60.00 price target on the stock, up previously from $45.00. Finally, analysts at TheStreet reiterated a “buy” rating on shares of Bristol-Myers Squibb in a research note to investors on Sunday. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $49.83.
Shares of Bristol-Myers Squibb (NYSE:BMY) opened at 52.02 on Tuesday. Bristol-Myers Squibb has a one year low of $30.64 and a one year high of $49.57. The stock’s 50-day moving average is $42.73 and its 200-day moving average is $42.60. The company has a market cap of $85.653 billion and a price-to-earnings ratio of 31.22. Bristol-Myers Squibb also was the target of unusually large options trading activity on Monday. Stock investors purchased 22,460 call options on the stock. This is an increase of 145% compared to the typical daily volume of 9,180 call options.
Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Wednesday, October 23rd. The company reported $0.46 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.44 by $0.02. The company had revenue of $4.07 billion for the quarter, compared to the consensus estimate of $4.02 billion. During the same quarter last year, the company posted $0.41 earnings per share. Bristol-Myers Squibb’s revenue was up 8.8% compared to the same quarter last year. Analysts expect that Bristol-Myers Squibb will post $1.74 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which is scheduled for Friday, November 1st. Stockholders of record on Friday, October 4th will be given a dividend of $0.35 per share. This represents a $1.40 dividend on an annualized basis and a yield of 2.69%. The ex-dividend date of this dividend is Wednesday, October 2nd.
Bristol-Myers Squibb Company (NYSE:BMY) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.